Immune thrombocytopenic purpura

Pediatric Clinics of North America

Volumn 49, Issue 5, 2002, Pages 911-928

  Di Paola, Jorge A ^a   Buchanan, George R ^b  

^a UNIVERSITY OF IOWA CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ASEPTIC MENINGITIS; BLEEDING; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; CATARACT; CELL FUNCTION; CHILL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE COURSE; DISEASE SEVERITY; FEVER; GENE EXPRESSION; HEADACHE; HIGH RISK PATIENT; HUMAN; HUMAN GENOME; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; MEDICAL DECISION MAKING; MIGRAINE; MOOD DISORDER; PHOTOPHOBIA; QUALITY OF LIFE; REGULATORY MECHANISM; REVIEW; THROMBOCYTE TRANSFUSION;

HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 0036774421     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(02)00027-5     Document Type: Review

References (102)

1. Harrington W, Minnich MS, Hollingsworth J, et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38:1-9.
2. Harrington W, Sprague C, Minnich V, et al. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953;38:433-65.
3. Shulman NR, Weinrach RS, Libre EP, Andrews HL. The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura. Trans Assoc Am Physicians 1965;78:374-90.
4. Eden OB, Lilleyman JS. Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group. Arch Dis Child 1992;67:1056-8.
5. George J, Woolf S, Raskob G, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
6. Vesely S, Buchanan GR, Cohen A, et al. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: Results of a survey of practicing pediatric hematology/oncology specialists. J Pediatr Hematol Oncol 2000;22:55-61.
7. Bolton-Maggs PHB. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 1997;350:620-3.
8. Kühne T, Freedman J, Semple JW, et al. Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura. J Pediatr 1997;130:17-24.
9. Medeiros D, Buchanan G. Current controversies in the management of idiopathic thrombocytopenic purpura during childhood. Pediatr Clin North Am 1996;43:757-69.
10. Blanchette V, Carcao M. Approach to the investigation and management of immune thrombocytopenic purpura in children. Semin Hematol 2000;37:299-314.
11. Buchanan G. Quantitative and qualitative platelet disorders. Clin Lab Med 1999;19:71-86.
12. Kühne T, Berchtold W, Tran VB, et al. Ethnicity and environment may affect the phenotype of immune thrombocytopenic purpura in children. Pediatr Res 2000;48:374-9.
13. Sutor A, Harms A, Kaufmehl K. Acute immune thrombocytopenia (ITP) in childhood: Retrospective and prospective survey in Germany. Semin Thromb Hemost 2001;27:253-67.
14. George J. Platelets. Lancet 2000;355:1531-9.
15. Berchtold P, McMillan R, Tani P, et al. Autoantibodies against platelet membrane glycoproteins in children with acute and chronic immune thrombocytopenic purpura. Blood 1989;74:1600-2.
16. Berchtold P, Muller D, Beardsley D, et al. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol 1997;96:477-83.
17. Imbach P, Tani P, Berchtold W, et al. Different forms of chronic childhood thrombocytopenic purpura defined by antiplatelet autoantibodies. J Pediatr 1991;118:535-39.
18. Tarantino MD, Madden RM, Fennewald DL, et al. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin. J Pediatr 1999;134:21-6.
19. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000;37:239-48.
20. Clarkson SB, Bussel JB, Kimberley RP, et al. Treatment of refractory immune thrombocytopenia purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986;8:1236-9.
21. Alves-Rosa F, Stanganelli C, Cabrera J, et al. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 2000;96:2834-40.
22. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1995;3:21-6.
23. Tworek D, Tang C, Ertem M, et al. In vivo alloimmune platelet destruction by anti-HPA-1A antibody is prevented by intravenous immunoglobulin in a dose dependent manner [abstract OC993]. Thromb Haemost 2001;86.
24. Ballem PJ, Segal GM, Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987;80:33-40.
25. Chang M, Nakagawa P, Schwartz M, et al. Inhibition of in vitro megakaryocytopoiesis by distinct ITP plasma subgroups. [abstract 2695] Blood 2000;96:627a.
26. Rinder HM, Tracey JB, Recht M, et al. Differences in platelet alpha-granule release between normals and immune thrombocytopenic patients and between young and old platelets. Thromb Haemost 1998;80:457-62.
27. Dame C. Thrombopoietin in thrombocytopenias of childhood. Semin Thromb Hemost 2001;27:215-25.
28. Murray J, Kelley P, Hogrefe W, et al. Childhood idiopathic thrombocytopenic purpura: Association with human parvovirus B19 infection. Am J Pediatr Hematol Oncol 1994;16:314-9.
29. Bamaba V. Viruses, hidden self-epitopes and autoimmunity. Immunol Rev 1996;152:47-66.
30. Gianani R, Sarvetnick N. Viruses, cytokines, antigens, and autoimmunity. Natl Acad Sci 1996;93:2257-9.
31. Rand ML, Wright JF. Virus-associated idiopathic thrombocytopenic purpura. Transfus Sci 1998;19:253-9.
32. Didier N, Bonnet F, Michaud M, et al. Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: Retrospective study of seven cases. Scand J Infect Dis 1998;30:115-8.
33. Nichols WC, Ginsburg D. Von Willebrand disease. Medicine (Baltimore) 1997;76:1-20.
34. Ronchi F, Cecchi P, Falcioni F, et al. Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine. Arch Dis Child 1998;78:273-4.
35. Semple J, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991;78:2619-25.
36. Ware R, Howard T. Elevated numbers of gamma-delta (γδ+) T lymphocytes in children with immune thrombocytopenic purpura. J Clin Immunol 1994;14:237-46.
37. Semple J, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: Relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996;87:4245-54.
38. Nugent DJ. Immune thrombocytopenic purpura: Why treat? J Pediatr 1999;134:3-4.
39. Nugent D, Wang Z, Sandborg C, et al. Reduced levels of IL-4 in immune medicated thrombocytopenia (ITP): Role of cytokine imbalances in autoimmune disease. Blood 1995;86(Suppl 1):S65.
40. Young G, Luban N, White JC. Giant platelet disorders in African-American children misdiagnosed as idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 1999;21:231-6.
41. DePiero AD, Lourie EM, Berman BW, et al. Recurrent immune cytopenias in two patients with DiGeorge/velocardiofacial syndrome. J Pediatr 1997;131:484-6.
42. Oda A, Ochs HD. Wiskott-Aldrich syndrome protein and platelets. Immunol Rev 2000;178:111-7.
43. Bettaieb A, Fromont P, Louache F, et al. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. Blood 1992;80:162-9.
44. Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 1987;66:337-40.
45. Aster R. Can drugs cause autoimmune thrombocytopenic purpura? Semin Hematol 2000;37:229-38.
46. Nieminen U, Peltola H, Syrjala MT, et al. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr 1993;82:267-70.
47. George J, Woolf S, Raskob G. Idiopathic thrombocytopenic purpura: A guideline for diagnosis and management of children and adults. Ann Med 1998;30:38-44.
48. Kelton JG, Powers PJ, Carter CJ. A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenic purpura. Blood 1982;6:1050-3.
49. Mueller-Eckhardt C, Mueller-Eckhardt G, Kayser W, et al. Platelet associated IgG, platelet survival, and platelet sequestration in thrombocytopenic states. Br J Haematol 1982;52:49-58.
50. Brighton TA, Evans S, Castaldi PA, et al. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996;88:194-201.
51. Chong B, Keng TB. Advances in the diagnosis of idiopathic thrombocytopenic purpura. Semin Hematol 2000;37:249-60.
52. Koh KR, Yamane T, Ohta K, et al. Pathophysiological significance of simultaneous measurement of reticulated platelets, large platelets and serum thrombopoietin in non-neoplastic thrombocytopenic disorders. Eur J Haematol 1999;63:295-301.
53. Koike Y, Yoneyama A, Shirai J, et al. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost 1998;79:1106-10.
54. Kurata Y, Hayashi S, Kiyoi T, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 2001;115:656-64.
55. Saxon BR, Blanchette VS, Butchart S, et al. Reticulated platelet counts in the diagnosis of acute immune thrombocytopenic purpura. J Pediatr Hematol Oncol 1998;20:44-8.
56. Calpin C, Dick P, Poon A, et al. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out Leukemia? Arch Pediatr Adolesc Med 1998;152:345-7.
57. Varon D, Dardik R, Shenkman B, et al. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997;85:283-94.
58. Medeiros D, Buchanan G. Major hemorrhage in children with idiopathic thrombocytopenic purpura: Immediate response to therapy and long-term outcome. J Pediatr 1998;133:334-9.
59. Lilleyman JS. Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology. Arch Dis Child 1994;71:251-3.
60. Iyordi H, Bessho F, Ookawa H, et al. Intracranial hemorrhage in children with immune thrombocytopenic purpura. Japanese Study Group on childhood ITP. Ann Hematol 2000;79:691-5.
61. Tarantino MD. On the conservative management of acute immune thrombocytopenia in children. J Pediatr 2001;138:787-8.
62. Schattner E, Bussel J. Mortality in immune thrombocytopenic purpura: Report of seven cases and consideration of prognostic indicators. Am J Hematol 1994:46;120-6.
63. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972;287:155-9.
64. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20.
65. Karpatkin S. Heterogeneity of human platelets. VI. Correlation ofplatelet function with platelet volume. Blood 1978;5:307-16.
66. Kenet G, Lubetsky A, Shenkman B, et al. Cone and platelet analyser (CPA): A new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998;101:255-9.
67. Kundu S, Heilmann E, Sio R, et al. Characterization of an in vitro platelet function analyzer, PFA-100™. Clin Appl Thrombosis/Hemostatis 1996;2:241-49.
68. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: A new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
69. Buchanan G, Adix L. Outcome measures and treatment endpoints other than platelet count in childhood idiopathic thrombocytopenic purpura. Semin Thromb Hemost 2001;27:277-85.
70. Buchanan GR, de Alarcon PA, Feig SA, et al. Acute idiopathic thrombocytopenic purpura - Management in childhood. Blood 1997;89:1464-5.
71. Nugent D, Imfeld K, Berman M. Cytokine stimulation by platelets and GPib immunodominant peptides. Suppl Thromb Haemost 2001;OC995:86.
72. Dickerhoff R, von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr 2000;37:629-32.
73. Davis HP, Raffles A: Childhood idiopathic thrombocytopenic purpura. Lancet 1997;350:1252.
74. George JN. Initial management of immune thrombocytopenic purpura in children: Is supportive counseling without therapeutic intervention sufficient? J Pediatr 2000;137:598-600.
75. Albayrak D, Islek I, Kalayci AG, et al. Acute immune thrombocytopenic purpura: A comparative study of very high oral doses of methylprednisolone and intravenously administered immune globulin. J Pediatr 1994;125:1004-7.
76. Pastore Y, Wacker P, Ozsahin H, et al. Emergency splenectomy in the management of intracranial hemorrhage in childhood immune thrombocytopenic purpura. J Pediatr Hematol Oncol 1999;21:306-7.
77. Bolton-Maggs PHB, Dickerhoff R, Vora A. The nontreatment of childhood ITP (or "The art of medicine consists of amusing the patient until nature cures the disease"). Semin Thromb Hemost 2001;27:269-75.
78. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31.
79. Kitchens CS, Pendergast JF. Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by glucocorticosteroid administration. Blood 1986;6:203-6.
80. Borgna-Pignatti C, Ruogolotto S, Nobili B, et al. A trial of high-dose dexamethasone therapy for chronic idiopathic thrombocytopenic purpura in childhood. J Pediatr 1997;130:13-6.
81. McMillan R, Longmire R, Yelenosky R. The effect of corticosteroids on human IgG synthesis. J Immunol 1976;116:1592-5.
82. McMillan R, Longmire RL, Tavassoli M, et al. In vitro platelet phagocytosis by splenic leukocytes in idiopathic thrombocytopenic purpura. N Engl J Med 1974;290:249-51.
83. Buchanan GR, Holtkamp CA. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial. Am J Pediatr Hematol Oncol 1984;6:355-61.
84. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993;123:989-95.
85. Carcao MD, Zipursky A, Butchart S, et al. Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998;424:71-4.
86. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344:703-07.
87. Bussel JB. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 2000;37:261-6.
88. Berkovitch M, Dolinski G, Tauber T, et al. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: Common and non-alarming. Int J Immunopharmacol 1999;21:411-5.
89. Kattamis AC, Shankar S, Cohen AR. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr 1997;13:281-3.
90. Ware RE, Zimmerman SA: Anti-D: Mechanisms of action. Semin Hematol 1998;35(Suppl 1):S14-22.
91. Freiberg A, Mauger D. Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children. Semin Hematol 1998;35(Suppl 1):23-27.
92. Andrew M, Blanchette VS, Adams M, et al. A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. J Pediatr 1992;120:522-7.
93. Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000;95:2523-9.
94. Mantadakis E, Buchanan GR. Elective splenectomy in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2000;22:148-53.
95. Kuhne T, Imbach P. Chronic immune thrombocytopenic purpura in childhood. Semin Thromb Hemost 1998;24:549-53.
96. Medeiros D, Buachanan GR. Idiopathic thrombocytopenic purpura: Beyond consensus. Curr Opin Pediatr 2000;12:4-9.
97. Hashizume M, Ohta M, Kishihara F, et al. Laparoscopic splenectomy for idiopathic thrombocytopenic purpura: Comparison of laparoscopic surgery and conventional open surgery. Surg Laparosc Endosc 1996;6:129-35.
98. Marcaccio MJ. Laparoscopic splenectomy in chronic idiopathic thrombocytopenic purpura. Semin Hematol 2000;37:267-74.
99. Pickering L. American Academy of Pediatrics: Immunization in special clinical circumstances. Red Book 2000;25:66-7.
100. Poullin P, Gabriel B. Thrombocytopenic purpura after recombinant hepatitis B vaccine. Lancet 1994;344:1293.
101. Quiquandon I, Fenaux P, Caulier MT, et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: A report on 53 cases. Br J Haematol 1990;74:223-8.
102. Warner MN, Moore JC, Warkentin TE, et al. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999;104:442-7.